Latest filing published 18 Sept 2026 for Harmony Biosciences Holdings, Inc., €24k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Kumar Budur discloses dealings in Harmony Biosciences Holdings, Inc. to SEC (Form 4). Over a trading history stretching from 24 January 2025 to 18 September 2026, the count stands at 23 filings.
No open-market purchase appears, only 7 sales worth €2.7M. Besides market trades, the filings include 4 share grants and 12 option exercises. 2026 to date brings no purchases and 7 sales.
The newest entry dates from 18 September 2026: an option exercise of €671k, in Harmony Biosciences Holdings, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations